MedTrace Logo

Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency

NCT03968211 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2024-03-29

No results posted yet for this study

Summary

This study is trying to find out if an undetectable serum immunoglobulin E (IgE) is a biomarker, or early sign of, the development of immune deficiency.

Conditions

  • Immune Deficiency

Interventions

BIOLOGICAL

Salmonella typhi polysaccharide vaccine

Salmonella typhi polysaccharide vaccine

Sponsors & Collaborators

  • CSL Behring

    collaborator INDUSTRY

  • Jeffrey Modell Foundation

    collaborator UNKNOWN

  • University of Virginia

    lead OTHER

Principal Investigators

  • Larry Borish, MD · University of Virginia

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2023-12-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03968211 on ClinicalTrials.gov